1. Home
  2. MDWD vs PVBC Comparison

MDWD vs PVBC Comparison

Compare MDWD & PVBC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MDWD
  • PVBC
  • Stock Information
  • Founded
  • MDWD 2000
  • PVBC 1913
  • Country
  • MDWD Israel
  • PVBC United States
  • Employees
  • MDWD N/A
  • PVBC N/A
  • Industry
  • MDWD Medicinal Chemicals and Botanical Products
  • PVBC Major Banks
  • Sector
  • MDWD Health Care
  • PVBC Finance
  • Exchange
  • MDWD Nasdaq
  • PVBC Nasdaq
  • Market Cap
  • MDWD 208.2M
  • PVBC 202.6M
  • IPO Year
  • MDWD 2014
  • PVBC 2015
  • Fundamental
  • Price
  • MDWD $20.72
  • PVBC $12.83
  • Analyst Decision
  • MDWD Strong Buy
  • PVBC Hold
  • Analyst Count
  • MDWD 2
  • PVBC 1
  • Target Price
  • MDWD $35.00
  • PVBC $12.50
  • AVG Volume (30 Days)
  • MDWD 49.2K
  • PVBC 251.0K
  • Earning Date
  • MDWD 08-13-2025
  • PVBC 07-28-2025
  • Dividend Yield
  • MDWD N/A
  • PVBC N/A
  • EPS Growth
  • MDWD N/A
  • PVBC N/A
  • EPS
  • MDWD N/A
  • PVBC 0.26
  • Revenue
  • MDWD $19,213,000.00
  • PVBC $50,244,000.00
  • Revenue This Year
  • MDWD $20.80
  • PVBC $9.73
  • Revenue Next Year
  • MDWD $26.92
  • PVBC $4.87
  • P/E Ratio
  • MDWD N/A
  • PVBC $49.31
  • Revenue Growth
  • MDWD N/A
  • PVBC N/A
  • 52 Week Low
  • MDWD $14.14
  • PVBC $9.67
  • 52 Week High
  • MDWD $22.51
  • PVBC $12.96
  • Technical
  • Relative Strength Index (RSI)
  • MDWD 64.88
  • PVBC 78.85
  • Support Level
  • MDWD $19.07
  • PVBC $12.60
  • Resistance Level
  • MDWD $19.55
  • PVBC $12.83
  • Average True Range (ATR)
  • MDWD 0.65
  • PVBC 0.17
  • MACD
  • MDWD 0.12
  • PVBC 0.03
  • Stochastic Oscillator
  • MDWD 94.01
  • PVBC 91.15

About MDWD MediWound Ltd.

MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.

About PVBC Provident Bancorp Inc. (MD)

Provident Bancorp Inc provides a range of banking products and services to small and medium-sized commercial customers. It attracts deposits from the general public and uses those funds to originate loans, commercial real estate, construction and land, and commercial business loans, and to invest in securities. The company lending activities include providing commercial real estate loans, multi-family residential real estate loans, commercial business loans, construction and land development loans, one-to four-family residential loans, home equity loans & lines of credit, and consumer loans.

Share on Social Networks: